Caution, this is an AI generated summary based on literature. This may have errors, see here for more.
Please share your feedback with us.
SNORA74A: SNORA74A is a dysregulated snoRNA that has been associated with shorter progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients [1]. It is one of several dysregulated snoRNAs, including SNORD116-18, SNORA70F, SNORD56, and SNORD1A, that have been identified as potential targets for leukemia therapy [1]. In acute myeloid leukemia (AML), it has been reported that SNORD114-1 regulates the cell cycle transition mediated by the Rb/p16 pathway [1]. Furthermore, studies on the sno/scaRNA profile have revealed dysregulated snoRNAs in different subtypes of leukemia, including SNORD109A, SNORD64, SNORD107, SNORA31, SNORA6, SNORA62, SNORA71C, and more [1] [2].
In terms of correlations with other biomarkers in pancreatic cancer patients measured by CA19-9 levels in serum samples, there were no significant correlations between the serum levels of RNAs WASF2 and ARF6 and CA19‐9 levels [3]. However, a significant correlation was observed between CA19‐9 levels and the serum levels of both RNAs WASF2 (R=0.221; 95% CI 0.100–0.500) and ARF6 (R=0.136; 95% CI 0.183–0.429) [3]. Additionally, a stronger correlation was observed between CA19‐9 levels and the serum level of SNORA74A (R=0.600; 95% CI 0.354–0.768) and SNORA25 (R=0.358; 95% CI 0.053–0.603) [2] [3].
mRNA interactions
1 total
Genome locations
Gene Ontology annotations
Ancestor Chart
Loading ontology ancestors...
Failed to load QuickGO Ancestor chart
Sequence
Sequence features are shown above as colored rectangles.
Zoom in and click to view details, or
Reset